8 Ounces a Day of POM Wonderful 100% Pomegranate Juice May Slow Progression of Carotid Intima-Media Thickness (CIMT) in Patients with Elevated Cardiovascular Disease Risk Factors, S...( LOS ANGELES Oct. 5 /- According to a ...),Health

LOS ANGELES, Oct. 5 /PRNewswire/ -- According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk. At 18 months, there was no reduction in the progression of CIMT in the group as a whole. However, further analysis revealed an indication that the rate of CIMT progression slowed in nearly one third of patients, those with elevated cardiovascular disease risk factors. This study was funded by POM Wonderful.

Conducted at Radiant Research in Chicago, IL, and University of Texas Southwestern Medical Center in Dallas, TX, this randomized, placebo-controlled, double-blind trial involved 289 subjects at varying degrees of moderate heart disease risk who consumed 8 ounces per day of either POM Wonderful 100% Pomegranate Juice or a placebo beverage. The trial's endpoint was the increase in CIMT, a measurement which includes both the artery wall itself as well as accumulated plaque. CIMT measurements were recorded at both 12 and 18 months after the treatment began.

The composite measurement of CIMT showed a significantly smaller value at 12 months in the pomegranate juice group compared to the control group (0.79 vs 0.81 mm, p = 0.022), although this difference was no longer significant at the end of the treatment period (0.79 vs 0.80 mm, p = 0.168). The results from post hoc exploratory analyses, which should be interpreted with caution, suggest that rate of CIMT progression may have been slowed in high-risk subgroups. Specifically, the authors found statistically lower CIMT values within several subgroups of patients with elevated cardiovascular risk
'/>"/>